

Policy Name	Clinical Policy – Perimetry (Visual Field Testing)
Policy Number	1319.00
Department	Clinical Strategy
Subcategory	Medical Management
Original Issue Date	03/21/2018
Current MPC/CCO Approval Date	07/09/2025
Current Effective Date	10/01/2025

Company Entities Supported (Select All that Apply):

☒ Superior Vision Benefit Management
☒ Superior Vision Services
☒ Superior Vision of New Jersey, Inc.
☒ Block Vision of Texas, Inc. d/b/a Superior Vision of Texas
☒ Davis Vision
 (Collectively referred to as 'Versant Health' or 'the Company')

ACRONYMS

IOP	Intraocular Pressure
OCT	Optical Coherence Tomography
VF	Visual Field

PURPOSE

To provide the medical necessity criteria to support the indications for perimetry and to render medical necessity determinations. Applicable procedure codes are also defined.

POLICY
A. Background

The visual field (VF) is the area within which objects may be seen when the eye is fixated. Perimetry, also known as visual field testing, detects both the extent of the visual fields as well as defects in the field of vision arising from the retina, optic nerve and visual pathways. Visual field tests are commonly performed using automated perimetry, which measures the ability to see points of light at varying locations and intensities. Many brands and configurations of computerized perimeters are available (e.g., Humphrey, Octopus, and Oculus). However, non-automated perimeters are occasionally utilized.

B. Medically Necessary

The medical necessity for initial diagnostic testing may begin with pertinent signs, symptoms, suspicion or disease, or medical history of a condition for which the examining physician needs further information.¹ VF testing is typically performed when the information from an eye exam is insufficient to assess the patient's condition, detect the presence of a disease process, or monitor progression of a condition. Visual field examinations may be considered medically necessary for any of the following:

1. The patient has a disorder of the eyelid(s) potentially affecting the visual field(s).
2. The patient has a visual field defect detected in gross visual field testing (e.g., confrontational testing).
3. The patient has a documented diagnosis of glaucoma or glaucoma suspect.
4. The patient has a documented disorder of the optic nerve, the retina, or the neurologic visual pathway.²
5. The patient has a recent intracranial hemorrhage, mass, or other specified disease
6. The patient has increased intracranial pressure measurement (with or without visual symptoms).
7. The patient has a recent occlusion / stenosis of cerebral arteries.
8. The patient has a history of a cerebral aneurysm, pituitary or occipital tumor potentially affecting the visual fields.
9. The patient is being evaluated for buphthalmos, congenital anomalies of the posterior segment or congenital ptosis.
10. The patient has a disorder of the orbit
11. The patient has sustained a significant eye injury.
12. The patient has unexplained visual loss
13. The patient has a recent exam with an abnormal appearance of pale or swollen optic nerve.
14. The patient is having new functional limitations which may be due to visual field loss (e.g., reports by family of patient bumping into objects).
15. The patient is taking a high risk medication that affects the visual system such as hydroxychloroquine or ethambutol;
16. The patient is being evaluated for transient visual loss;
17. Repeat testing is appropriate based upon the type and natural history of the disorder, the physical findings, and the patient's symptoms.

C. Not Medically Necessary

Gross visual field testing (e.g., confrontation testing) is included in general ophthalmological services and should not be reported separately.

¹ McKendrick, 2024

² Banc, 2024.

D. Documentation

Medical necessity must be supported by adequate and complete documentation in the patient's medical record that describes the procedure and the medical rationale for it as in requirements above. For all retrospective reviews, the full medical care plan must be available.

All listed items must be available upon request. Every page of the record must be legible and include appropriate patient identification information (e.g., complete name, date(s) of service). Services provided or ordered must be signed by the physician, either in a handwritten or electronic signature. Stamped signatures are not acceptable.

Each visual field test requires an interpretation and report which includes:

1. Physician's order for test with medical rationale and the medical plan of care
2. Date performed
3. Reliability of the visual fields
4. Patient cooperation
5. Visual field findings (e.g., printout) and interpretation
6. When applicable, comparison of current results from prior tests in terms of progression, resolution or stability of the visual fields.
7. Evaluation and diagnosis
8. Impact on treatment and prognosis
9. The medical record must contain copies of the digital images and be available upon request.

E. PROCEDURAL DETAIL

CPT Codes	
92081	Visual field examination, unilateral or bilateral, with interpretation and report; limited examination (e.g., tangent screen, Autoplot, arc perimeter, or single stimulus level automated test, such as Octopus 3 or 7 equivalent)
92082	Visual field examination, unilateral or bilateral, with interpretation and report; intermediate examination (e.g., at least 2 isopters on Goldmann perimeter, or semiquantitative, automated suprathreshold screening program, Humphrey suprathreshold automatic diagnostic test, Octopus program 33)
92083	Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (e.g., Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30 degrees, or quantitative, automated threshold perimetry, Octopus programs G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 2-4-2, or 30/60-2)

DISCLAIMER, LIMITATIONS AND EXCLUSIONS

This clinical policy is provided for information purposes only and does not constitute medical advice. Versant Health, Inc., and its affiliates (the “Company”) do not provide health care services and cannot guarantee any results or outcomes. Treating doctors are solely responsible for determining what services or treatments to provide for their patients. Patients (members) should always consult their doctor before making any decisions about medical care.

Subject to applicable law, compliance with this clinical policy is not a guarantee of coverage or payment. Coverage is based on the terms of an individual's particular benefit plan document, which may not include the service(s) or procedure(s) addressed in this clinical policy. The terms of the individual's specific benefit plan are always determinative.

Every effort has been made to ensure that the information in this clinical policy is accurate and complete. However, the company does not guarantee that there are no errors in this policy or that the display of this file on a website is without error. The company and its employees are not liable for any errors, omissions, or other inaccuracies in the information, product, or processes disclosed herein. Neither the Company nor the employees represent that the use of such information, products, or processes will infringe on privately owned rights. In no event shall the Company be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information, product, or process.

COMPANY'S COPYRIGHT STATEMENT Except for any copyrights described below, this clinical policy is confidential and proprietary, and no part of this clinical policy may be copied, distributed or used without Versant Health, or its applicable affiliates expressing prior written approval.

AMA COPYRIGHT STATEMENT CPT© 2002-2025 is the copyright of the American Medical Association. All Rights Reserved. CPT™ is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained.

RELATED POLICIES AND PROCEDURES
--

n/a

DOCUMENT HISTORY

<i>Approval Date</i>	<i>Revision</i>	<i>Effective Date</i>
03/21/2018	Initial policy.	03/21/2018
10/18/2019	Annual review and format change.	11/01/2019

08/19/2020	Annual review; no criteria changes.	12/01/2020
07/07/2021	Annual review; no criteria changes.	10/01/2021
07/06/2022	Annual review; no criteria changes.	08/01/2022
07/12/2023	Clarify indications include glaucoma suspect and suspicion of disease; clarify high risk medications include ethambutol.	09/01/2023
07/10/2024	Annual review; no criteria changes.	09/01/2024
07/09/2025	Annual review; no criteria changes.	10/01/2025

REFERENCES AND SOURCES

1. Anderson C, Blaha GR, Marx JL. Humphrey visual field findings in hydroxychloroquine toxicity. *Eye (Lond)*. 2011;25(12):1535-1545. doi:10.1038/eye.2011.245.
2. Anderson AJ, Asokan R, Murata H, et.al. Detecting glaucomatous progression with infrequent visual field testing. *Ophthalmic Physiol Opt*. 2018 Mar;38(2):174-182. doi: 10.1111/opo.12439. Epub 2018 Jan 8. PMID: 29315705.
3. Banc A, Kedar S. Interpretation of the Visual Field in Neuro-ophthalmic Disorders. *Curr Neurol Neurosci Rep*. 2024 Mar;24(3):67-81. doi: 10.1007/s11910-024-01332-3. Epub 2024 Jan 30. PMID: 38289405.
4. Cahill KV, Bradley EA, Meyer DR. et.al. Functional indications for upper eyelid ptosis and blepharoplasty surgery: a report by the American Academy of Ophthalmology. *Ophthalmology*. 2011 Dec;118(12):2510-7. doi: 10.1016/j.ophtha.2011.09.029. Epub 2011 Oct 22. PMID: 22019388.
5. De Moraes CG, Liebmann JM, Levin LA. Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma. *Prog Retin Eye Res*. 2017; 56:107-147. doi: 10.1016/j.preteyeres.2016.10.001.
6. Drummond PD, Anderson M. Visual field loss after attacks of migraine with aura. *Cephalalgia*. 1992;12(6):349-352. doi:10.1111/j.1468-2982.1992.00349.x
7. Fidalgo BM, Crabb DP, Lawrenson JG. Methodology and reporting of diagnostic accuracy studies of automated perimetry in glaucoma: evaluation using a standardized approach. *Ophthalmic Physiol Opt*. 2015 May;35(3):315-23. doi: 10.1111/opo.12208. PMID: 25913874.
8. Hekmatjah N, Kumar A, Yu Y, et al. Visual Field Testing Frequency and Associations in Children With Glaucoma. *J Glaucoma*. 2024;33(7):499-504. doi:10.1097/IJG.0000000000002406.
9. Ho JC. Reduction in mean deviation values in automated perimetry in eyes with multifocal compared to monofocal intraocular lens implants. *Am J Ophthalmol*. 2014;158(5):1100–1101. doi: 10.1016/j.ajo.2014.08.030.
10. Johnson CA. Psychophysical factors that have been applied to clinical perimetry. *Vision Res*. 2013; 90:25–31. doi: 10.1016/j.visres.2013.07.005.
11. Johnson CA, Wall M, Thompson HS. A history of perimetry and visual field testing. *Optom Vis Sci*. 2011 Jan;88(1): E8-15. doi: 10.1097/OPX.0b013e3182004c3b. PMID: 21131878.
12. Keeffe JE, Charlton JL. Visual fields and driving. *Clin Exp Ophthalmol*. 2007;35(7):594-595. doi:10.1111/j.1442-9071.2007.01601.x.

13. McKendrick AM, Turpin A. Understanding and identifying visual field progression. Clin Exp Optom. 2024 Mar;107(2):122-129. doi: 10.1080/08164622.2024.2316002. Epub 2024 Mar 11. PMID: 38467126.
14. McKendrick AM, Turpin A. Understanding and identifying visual field progression. Clin Exp Optom. 2024 Mar;107(2):122-129. doi: 10.1080/08164622.2024.2316002. Epub 2024 Mar 11. PMID: 38467126.
15. Nouri-Mahdavi K. Selecting visual field tests and assessing visual field deterioration in glaucoma. Can J Ophthalmol. 2014;49(6):497-505. doi: 10.1016/j.jcjo.2014.10.002. 2021 Mar 1;32(2):92-97. doi: 10.1097/ICU.0000000000000735. PMID: 33443958.
16. Yusuf IH, Sharma S, Luqmani R, et al. Hydroxychloroquine retinopathy. Eye (Lond). 2017 Jun;31(6):828-845. doi: 10.1038/eye.2016.298. Epub 2017 Mar 10. PMID: 28282061; PMCID: PMC5518824.

SOURCES

1. American Academy of Ophthalmology, Glaucoma Committee, Hoskins Center for Quality Eye Care Primary Angle Closure Disease; 2020. <https://www.aao.org/education/preferred-practice-pattern/primary-angle-closure-disease-ppp> . Accessed 5/2025. American Academy of Ophthalmology, Idiopathic Epiretinal Membrane and Vitreomacular Traction; PPP 2024. <https://www.aao.org/education/preferred-practice-pattern/idiopathic-epiretinal-membrane-vitreomacular-tract-2>. Accessed 5/2025.
2. American Academy of Ophthalmology, Idiopathic Macular Hole PPP 2024. <https://www.aao.org/education/preferred-practice-pattern/idiopathic-macular-hole-ppp>. Accessed 5/2025.
3. American Academy of Ophthalmology, Posterior Vitreous Detachment, Retinal Breaks and Lattice Degeneration. PPP 2024. <https://www.aao.org/education/preferred-practice-pattern/posterior-vitreous-detachment-retinal-breaks-latti> . Accessed 5/2025.
4. American Optometric Association. Comprehensive Eye exam. <https://www.aoa.org/healthy-eyes/caring-for-your-eyes/eye-exams?sso=y>. Accessed 5/2025.
5. American Optometric Association. Eye Care of the patient with diabetes mellitus. 2nd edition. <https://www.aoa.org/AOA/Documents/Practice%20Management/Clinical%20Guidelines/EO%20Guidelines/Eye%20Care%20of%20the%20Patient%20with%20Diabetes%20Mellitus%20C%20Second%20Edition.pdf> . Accessed 5/2025.
6. CMS Billing and Coding: Visual Fields Testing. A56551. <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56551&ver=30&=>. Accessed 5/2025.
7. CMS MCD Computer Enhanced Perimetry. <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=261&ncdver=1&keywordtype=starts&keyword=perimet&bc=0/> Accessed 5/2025.